Patient Advocacy Committee

Chair: Paul Hastings, OncoMed Pharmaceuticals Inc.
Staff Contacts:  Frederick Bittenbender, Executive Vice President, Public Affairs, fbittenbender@bio.org

Subject Matter/Jurisdiction:  The committee oversees BIO’s Alliance Development initiatives and strategic engagement with third party stakeholders including patient advocacy, provider, and other organizations committed to ensuring access to innovative therapies.  

Roster: 

Chairman:
Paul Hastings, President & CEO, OncoMed Pharmaceuticals Inc.

Members:
Adrian Adams,  President & CEO, Auxilium Pharmaceuticals, Inc.
Stuart Arbuckle,  EVP & CCO, Vertex Pharmaceuticals Inc.
Ron Cohen,  President & CEO, Acorda Therapeutics, Inc.
Michelle Dipp, Chief Executive Officer, Ovascience
Julie Gerberding, President, Merck & Co., Inc.
Jeffrey Hatfield, Chief Executive Officer, Vitae Pharmaceuticals, Inc.
Rachel King, President & CEO, GlycoMimetics, Inc.
Nick Leschly, President & CEO, bluebird bio
Gail Maderis, President & CEO, BayBio
David  Meeker, Chief Executive Officer, Genzyme Corporation
Arlene Morris, President & CEO,  Syndax Pharmaceuticals, Inc.
Richard Pops, Chairman & CEO,  Alkermes
Raymond Sacchetti, Sr. Vice President, U.S. Access & Government Affairs, Bristol-Myers Squidd
Jay Siegel, Chief Biotechnology Officer & Head, Scientific Strategy & Policy, Johnson & Johnson
H. Thomas Watkins, Chair Emeritus, BIO
Allen Waxman, Senior VP & General Counsel, Eisai, Inc. 
Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, Inc. 
 

 

Hide Date: 
Hide Date
Hide Add This: 
Hide Add This